Harvey J. Berger M.D., Chairman and Chief Executive Officer of ARIAD Pharmaceuticals, presides over the opening bell.

ARIAD is engaged in the discovery and development of breakthrough medicines to treat cancer by regulating cell signaling with small molecules. ARIAD is developing a comprehensive approach to patients with cancer that addresses the greatest medical need -- aggressive and advanced-stage cancers for which current treatments are inadequate.

ARIAD has a global partnership with Merck & Co., Inc. to develop and commercialize deforolimus, ARIAD's lead cancer product candidate in late-stage clinical development in a broad range of cancers. ARIAD's second oncology product candidate, oral AP24534, is a novel multi-targeted kinase inhibitor entering Phase 1 clinical development. ARIAD has an exclusive license to pioneering technology and patents related to certain NF-kB treatment methods, and the discovery and development of drugs to regulate NF-kB cell-signaling activity, which may be useful in treating certain diseases.

Additional information about ARIAD can be found on the web at http://www.ariad.com.

Organizations interested in obtaining NASDAQ-listed company bell ringing ceremony photographs for press purposes, must first receive approval from the listed company before requesting photographs from NASDAQ. Please provide the company contact information from whom you received approval to Jolene Libretto at jolene.libretto@nasdaq.com. Kindly credit © 2008, The Nasdaq Stock Market, Inc. Reprinted with permission.

For all other photography inquiries, please contact NASDAQ’s photographer, Rob Tannenbaum at rob.tannenbaum@nasdaq.com.

© 2008, The NASDAQ OMX Group, Inc. Reprinted with permission.

Copyright | Disclaimer | Trademarks | Privacy Statement | Contact Us | Help | Search